Rainbow Childrens Medicare Ltd Q3 FY26 Earnings Analysis

Published 11 Aug 2026 | Healthcare Services | Market Cap: ₹16.2K Cr

Price

1,504

Market Cap

₹16.2K Cr

P/E Ratio

56.7

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Rainbow Childrens Medicare Ltd Q3 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Rainbow Childrens Medicare Ltd share price analysis?

Rainbow Childrens Medicare Ltd currently shows a neutral. The stock trades at a P/E of 56.7 with a market cap of ₹16,236 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rainbow Childrens Medicare Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Healthcare Services this season

  • Krishna Institute of Medical Sciences Ltd (Q3 FY26)

    Krishna Institute of Medical Sciences Ltd Q3 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Marke

  • Dr Lal Pathlabs Ltd (Q3 FY26)

    Dr Lal Pathlabs Ltd Q3 FY26 quarterly results analysis. The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of

  • Healthcare Global Enterprises Ltd (Q3 FY26)

    Healthcare Global Enterprises Ltd Q3 FY26 quarterly results analysis. Overall revenue growth expected to outpace industry, sustaining over 15% per annum. Market

  • Narayana Hrudayalaya Ltd (Q3 FY26)

    Narayana Hrudayalaya Ltd Q3 FY26 quarterly results analysis. Hospital patient flow in new hospitals is still establishing; initially, high minimum guarantees ca